Abstract:Background: Vaccination is recognized as the only practical measure for preventing Japanese encephalitis. Production shortage, costs, and issues of licensure impair vaccination programmes in many affected countries. Concerns over vaccine effectiveness and safety also have a negative impact on acceptance and uptake. Objectives: To evaluate vaccines for preventing Japanese encephalitis in terms of effectiveness, adverse events, and immunogenicity. Search strategy: In March 2007, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2007, Issue 1), MEDLINE, EMBASE, LILACS, BIOSIS, and reference lists. We also attempted to contact corresponding authors and vaccine companies. Selection criteria: Randomized controlled trials (RCTs), including cluster-RCTs, comparing Japanese encephalitis vaccines with placebo (inert agent or unrelated vaccine), no intervention, or alternative Japanese encephalitis vaccine. Data collection and analysis: Authors independently extracted data and assessed methodological quality. Dichotomous data were compared with relative risks and a 95% confidence interval (CI), and converted into percentage vaccine efficacy. Main results: Eight RCTs involving 358,750 participants were included. These trials investigated two available and three pre-licensure vaccines. Two RCTs assessing efficacy of the commercially available inactivated Nakayama vaccine were identified. A two-dose schedule of the licensed vaccine provided significant protection of 95% (95% CI 10% to 100%) for one year only, while two doses of an unpurified precursor vaccine protected children by 81% (95% CI 45% to 94%) in year one and by 59% (95% CI 2% to 83%) in year two. Serious adverse events were not observed. Mild and moderate episodes of injection site soreness, fever, headache, and nausea were reported in less than 6% of children receiving inactivated vaccine compared to 0.6% of unvaccinated controls. One cluster-RCT compared the live-attenuated SA14-14-2 vaccine (widely used in China) with no intervention measuring adverse events. Fever was reported in 2.7% of vaccinees compared to 3.1% of controls, while 0.1% of both groups suffered diarrhoea or seizures. Four small pre-licensure RCTs assessing a genetically engineered vaccine and two cell culture-derived inactivated vaccines revealed high immunogenicity and relative safety. Authors' conclusions: Only one of the three currently used vaccines has been assessed for efficacy in a RCT. Other RCTs have assessed their safety, however, and they appear to cause only occasional mild or moderate adverse events. Further trials of effectiveness and safety are needed for the currently used vaccines, especially concerning dose levels and schedules. Trials investigating several new vaccines are planned or in progress.

Evaluation of the Impact of the Japanese Encephalitis Vaccine Included in an Expanded Immunization Program on the Reported Incidence Rate of Japanese Encephalitis in Gansu Province-Based on Interrupted Time Series

Impact of the expanded program on immunization on the incidence of Japanese encephalitis in different regions of Mainland China: An interrupt time series analysis

Adults in Northwest China Experienced the Largest Outbreak of Japanese Encephalitis in History 10 Years after the Japanese Encephalitis Vaccine Was Included in the National Immunization Program: A Retrospective Epidemiological Study

Reduction patterns of Japanese encephalitis incidence following vaccine introduction into long-term expanded program on immunization in Yunnan Province, China

Effect of different vaccine strategies for the control of Japanese encephalitis in mainland China from 1961 to 2020: A quantitative analysis

Epidemiology of Japanese Encephalitis in China (2004–2015)

Long-Term Epidemiological Dynamics of Japanese Encephalitis Infection in Gansu Province, China: A Spatial and Temporal Analysis.

Trends in temporal and spatial changes of Japanese encephalitis in Chinese Mainland, 2004-2019: a population-based surveillance study

A comparison of clinical manifestations of Japanese encephalitis between children and adults in Gansu Province, Northwest China (2005–2020)

Mass immunisation to eradicate Japanese encephalitis: Real-world evidence from Guizhou Province in 2005–2021

Impact of vaccination against Japanese encephalitis in endemic countries

Epidemic Changes and Spatio-Temporal Analysis of Japanese Encephalitis in Shaanxi Province, China, 2005–2018

EPIDEMIOLOGICAL ANALYSIS ON ENCEPHALITIS B IN BAOJI FROM 1950 TO 2008

Investigating Nonspecific Effects of the Live-Attenuated Japanese Encephalitis Vaccine on Lower Respiratory Tract Infections in Children Aged 25-35 Months: Retrospective Cohort Study

Long-Term Neurological Sequelae and Disease Burden of Japanese Encephalitis in Gansu Province, China

Analysis on the Surveillance Data for Encephalitis and Meningitis in Yichang Prefecture,Hubei Province(2006-2009)

Spatiotemporal Patterns of Japanese Encephalitis in China, 2002–2010

Vaccines for preventing Japanese encephalitis

Assessment of effectiveness of Japanese encephalitis vaccination in West Bengal, India using sample positivity rate as an alternate measure

Epidemiology of Japanese Encephalitis in Central India after Implementing Immunization

Surveillance and analysis of healthy people′s antibody against Japanese encephalitis in Tianjin in 2007